Claims

1. Use of AZD1390, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in a method of treatment a CNS tumour,, wherein said treatment comprises the separate, sequential or simultaneous administration of i) a total daily dose of about 300 mg of said AZD1390, optionally in the form of a pharmaceutically acceptable salt thereof, and ii) radiation therapy, to said subject.

2. Use of AZD1390, or a pharmaceutically acceptable salt thereof, according to claim 1, wherein AZD1390 or a pharmaceutically acceptable salt thereof is to be administered continuously whilst radiotherapy is being administered.

3. Use of AZD1390, or a pharmaceutically acceptable salt thereof, according to either claim 1 or claim 2, wherein, whilst radiotherapy is being delivered, AZD1390 or a pharmaceutically acceptable salt thereof is to be administered only on the days that radiotherapy is to be administered.

4. Use of AZD1390, or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 3, wherein AZD1390 or a pharmaceutically acceptable salt thereof is to be administered after the last dose of radiotherapy in a cycle as an adjuvant phase.

5. Use of AZD1390, or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 4, wherein the AZD1390 or a pharmaceutically acceptable salt thereof is to be administered orally.

6. Use of AZD1390, or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 5, wherein the AZD1390 or a pharmaceutically acceptable salt thereof is in tablet form.

7. Use of AZD1390, or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 6, wherein the total daily dose of AZD1390 is up to 340 mg, 330 mg, 320 mg, 310 mg, or 300 mg.

8. Use of AZD1390, or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 7, wherein the total daily dose of AZD1390 is at least 250, 260 mg, 270 mg, 280 mg, 290 mg, or 300 mg.

9. Use of AZD1390, or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 6, wherein the total daily dose of AZD1390 is 300 mg.

10. Use of AZD1390, or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 9, wherein AZD1390 is to be administered once a day.

11. Use of AZD1390, or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 9, wherein AZD1390 is to be administered twice a day.

12. Use of AZD1390, or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 11, wherein the CNS tumour is selected from glioblastoma, IDH mutant glioma (WHO Grade 2-4), ependymoma, high grade meningioma, paediatric high-grade glioma, Diffuse Intrinsic Pontine Glioma (DIPG), choroid plexus carcinoma, astrocytoma (such as Grade 4 astrocytoma), adult and/or paediatric medulloblastoma and metastatic CNS tumour (such as leptomeningeal disease).

13. Use of AZD1390, or a pharmaceutically acceptable salt thereof, according to claim 12, wherein the CNS tumour is glioblastoma.

14. Use of AZD1390, or a pharmaceutically acceptable salt thereof, according to claim 13, wherein the CNS tumour is primary glioblastoma.

15. Use of AZD1390, or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 14, wherein the radiotherapy is intensity-modulated radiation therapy (IMRT).

16. Use of AZD1390, or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 14, wherein the radiotherapy is whole brain radiation therapy (WBRT) or partial brain radiation therapy (PBRT).

17. Use of AZD1390, or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 16, wherein the radiation therapy is fractionated radiation therapy.

18. Use of AZD1390, or a pharmaceutically acceptable salt thereof, according to claim 17, wherein the radiation therapy fractions are to be administered in sequential days.

19. Use of AZD1390, or a pharmaceutically acceptable salt thereof, according to claim 17, wherein the radiation therapy fractions are to be administered for some days sequentially, with some rest days.

20. Use of AZD1390, or a pharmaceutically acceptable salt thereof, according to claim 19, wherein the radiation therapy fractions are to be administered for five days sequentially, followed by two rest days.

21. Use of AZD1390, or a pharmaceutically acceptable salt thereof, according to any one of claims 17 to 20, wherein the total dose of radiotherapy is at least 20 Gy, at least 30 Gy, at least 40 Gy, or at least 50 Gy.

22. Use of AZD1390, or a pharmaceutically acceptable salt thereof, according to any one of claims 17 to 21, wherein the total dose of radiotherapy is less than 70 Gy, less than 60 Gy, less than 50 Gy, or less than 40 Gy.

23. Use of AZD1390, or a pharmaceutically acceptable salt thereof, according to any one of claims 17 to 20, wherein the total dose of radiotherapy is 60 Gy.

24. Use of AZD1390, or a pharmaceutically acceptable salt thereof, according to any one of claims 17 to 20, wherein the total dose of radiotherapy is 35 Gy.

25. Use of AZD1390, or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 14, wherein the radiotherapy is delivered by IMRT with daily fractions of 2.0 Gy over 4 to 6 weeks on 5 days out of 7, such as weekdays only.